Emerging Therapeutic Options for Medullary Thyroid Cancer and Differentiated Thyroid Cancer

Co-provided by: A. Webb Roberts Center for CME of Baylor Health Care System and CancerNet.

This activity is supported by independent educational grants from AstraZeneca, and Genzyme, a Sanofi company.

Specialty: Hematology/Oncology

Release date: June 6, 2014

Valid through: June 6, 2015

Target Audience:

This webcast is designed to meet the educational needs of medical oncologists and other health care professionals who diagnose, treat, and manage patients with thyroid cancer.

Program Overview:

This webcast is intended to improve care of patients with thyroid cancer by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

This program consists of 2 continuing education activites.

Module 1 — Marcia Brose, MD — 0.5 AMA PRA Category 1™ Credit Hours

Module 2 — Ezra Cohen, MD — 0.5 AMA PRA Category 1™ Credit Hours